[
    [
        {
            "time": "2018-03-15",
            "original_text": "The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, FPI, FIZZ, ACAD, TTPH and ABBV",
            "features": {
                "keywords": [
                    "Klein Law Firm",
                    "Class Actions",
                    "Shareholders",
                    "MD",
                    "FPI",
                    "FIZZ",
                    "ACAD",
                    "TTPH",
                    "ABBV"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "legal",
                    "investments"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, FPI, FIZZ, ACAD, TTPH and ABBV",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "AbbVie Posts Positive Data on Elagolix for Uterine Fibroids",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Elagolix",
                    "Positive Data",
                    "Uterine Fibroids"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Posts Positive Data on Elagolix for Uterine Fibroids",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "FDA",
                    "SBLA",
                    "Empliciti",
                    "Pomalidomide",
                    "Dexamethasone"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "regulatory"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]